Cyrus M.

Investigates heart failure recovery, rate control, and prevention of venous thromboembolism in acute settings.

• Beta‑blocker discontinuation in recovered heart failure
• Ivabradine use for heart‑rate control in septic shock
• Rivaroxaban versus low‑molecular‑weight heparin for post‑trauma thromboprophylaxis
• Management of deep venous thrombosis in Behçet’s syndrome
• Therapeutic considerations in Takayasu arteritis with cerebrovascular involvement

Emphasis on cardiovascular outcomes in critically ill patients.

Targets optimization of antimicrobial regimens for complex bacterial and viral infections.

• Non‑inferior regimens for Mycobacterium avium complex pulmonary disease
• Carbapenem‑sparing strategies for ESBL‑producing Enterobacteriaceae
• Rifabutin versus rifampicin in staphylococcal prosthetic joint infection
• Antiretroviral and antiviral combination for HIV/Hepatitis B co‑infection
• Adjunctive trimodulin in severe pneumonia

Clinical trials integrate pharmacokinetic monitoring and resistance profiling.

Explores targeted biologic and immunosuppressive therapies for systemic vasculitis and related disorders.

• Tocilizumab efficacy in giant cell arteritis with cerebrovascular involvement
• Salvage regimens for refractory granulomatosis with polyangiitis
• Obinutuzumab for refractory cryoglobulinemia vasculitis
• Management of non‑infectious active cryoglobulinemia
• Therapeutic approaches for Takayasu arteritis

Studies often assess remission rates and imaging outcomes.

Focuses on neoadjuvant and adjuvant strategies for colorectal cancer guided by molecular markers.

• Neo‑adjuvant FOLFOX chemotherapy in resectable colon carcinoma
• Circulating tumor DNA‑directed adjuvant therapy
• Survival benefit of intensified chemotherapy in ctDNA‑positive patients
• Integration of targeted agents in elderly colorectal cancer cohorts
• Evaluation of chemotherapy sequencing based on molecular risk

Collaboration with surgical oncology units for peri‑operative trials.